Temporal Changes in Maternal Serum Biochemical Markers of Trisomy 21 across the First and Second Trimester of Pregnancy
Open Access
- 1 November 2002
- journal article
- research article
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 39 (6) , 567-576
- https://doi.org/10.1177/000456320203900604
Abstract
Background: Many maternal serum markers show concentration changes in Down's syndrome pregnancies but the magnitude of the change in median marker levels varies with gestation. To date these changes have not been accurately specified. Methods: The trends in marker median levels between 6 and 20 weeks of gestation were examined for alphafetoprotein (AFP), free β human chorionic gonadotrophin (F β-hCG), total human chorionic gonadotrophin (ThCG) and pregnancy-associated plasma protein A (PAPP-A) by a meta-analysis of data obtained from our collaborative studies and routine screening programmes for Down's syndrome over a 10-year period. Data were available from between 709 and 1082 Down's syndrome pregnancies and from between 14 607 and 153 909 unaffected pregnancies for each marker. The median multiple of the median (MoM) and mean log10MoM for each marker at each completed week of gestation were estimated and the trend with gestation smoothed using a weighted least squares regression model. Results: The gestational ages at which maximum separation of marker levels occurred, comparing affected and unaffected pregnancies, and the respective regressed median MoMs and mean log10MoMs, were: for AFP at 16 weeks, 0·72 MoM, 0·14288 log10MoM; for F β-hCG at 15 weeks, 2·24 MoM, 0·35034 log10MoM; for ThCG at 16 weeks, 1·93 MoM, 0·28548 log10MoM, as well as before 8 weeks (< 0·65 MoM, 0·18853 log10MoM); and for PAPP-A before 8 weeks, < 0·33 MoM, 0·47727 log10MoM. Conclusion: There is significant temporal variation in mean log10MoM values for the screening markers investigated. Screening algorithms, modified to take account of this variation, should allow more accurate gestation-specific risks to be calculated in individual pregnancies.Keywords
This publication has 27 references indexed in Scilit:
- What is the true fetal loss rate in pregnancies affected by trisomy 21 and how does this influence whether first trimester detection rates are superior to those in the second trimester?Prenatal Diagnosis, 2001
- One stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimesterBJOG: An International Journal of Obstetrics and Gynaecology, 2000
- Second trimester prenatal screening for Down's syndrome using alpha‐fetoprotein and free beta hCG: a seven year reviewBJOG: An International Journal of Obstetrics and Gynaecology, 1999
- A screening program for trisomy 21 at 10–14 weeks using fetal nuchal translucency, maternal serum free β‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐AUltrasound in Obstetrics & Gynecology, 1999
- Antenatal Screening for Down's SyndromeJournal of Medical Screening, 1997
- Impact of a Regional Screening Programme Using Maternal Serum a Fetoprotein (AFP) and Human Chorionic Gonadotrophin (hCG) on the Birth Incidence of Down's Syndrome in the West of ScotlandJournal of Medical Screening, 1994
- Second‐trimester maternal serum screening using alpha‐fetoprotein, human chorionic gonadotrophin, and unconjugated oestriol: Experience of a regional programmePrenatal Diagnosis, 1994
- Maternal serum Down syndrome screening: Free β-protein is a more effective marker than human chorionic gonadotropinAmerican Journal of Obstetrics and Gynecology, 1990
- The Mathematical Basis of Multivariate Risk Screening: With Special Reference to Screening for Down's Syndrome Associated PregnancyAnnals of Clinical Biochemistry: International Journal of Laboratory Medicine, 1990
- Maternal serum screening for Down's syndrome in early pregnancy.BMJ, 1988